Resultats globals: 3 registres trobats en 0.01 segons.
Articles, 3 registres trobats
Articles 3 registres trobats  
1.
12 p, 653.9 KB HIV-1 Gag mutations alone are sufficient to reduce darunavir susceptibility during virological failure to boosted PI therapy / Blanch Lombarte, Oscar (Institut Germans Trias i Pujol) ; Santos, José Ramón (Institut Germans Trias i Pujol. Institut de Recerca de la Sida IrsiCaixa) ; Peña, Ruth (Institut Germans Trias i Pujol. Institut de Recerca de la Sida IrsiCaixa) ; Jiménez Moyano, Esther (Institut Germans Trias i Pujol. Institut de Recerca de la Sida IrsiCaixa) ; Clotet, Bonaventura (Institut Germans Trias i Pujol. Institut de Recerca de la Sida IrsiCaixa) ; Paredes, Roger (Institut Germans Trias i Pujol. Institut de Recerca de la Sida IrsiCaixa) ; Prado, Julia G. (Institut Germans Trias i Pujol) ; Universitat Autònoma de Barcelona
Virological failure (VF) to boosted PIs with a high genetic barrier is not usually linked to the development of resistance-associated mutations in the protease gene. From a cohort of 520 HIV-infected subjects treated with lopinavir/ritonavir or darunavir/ritonavir monotherapy, we retrospectively identified nine patients with VF. [...]
2020 - 10.1093/jac/dkaa228
Journal of Antimicrobial Chemotherapy, Vol. 75 (june 2020) , p. 2535-2546  
2.
11 p, 1.6 MB Week 96 efficacy and safety results of the phase 3, randomized EMERALD trial to evaluate switching from boosted-protease inhibitors plus emtricitabine/tenofovir disoproxil fumarate regimens to the once daily, single-tablet regimen of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in treatment-experienced, virologically-suppressed adults living with HIV-1 / Eron, J.J. (University of North Carolina School of Medicine) ; Orkin, C. (Department of HIV Medicine. Royal Free London NHS Foundation Trust) ; Cunningham, D. (Pueblo Family Physicians) ; Pulido, F. (Hospital General Universitario de Alicante (Alacant, País Valencià)) ; Post, F. (King's College Hospital NHS Foundation Trust) ; De Wit, S. (Saint-Pierre University Hospital. Université Libre de Bruxelles) ; Lathouwers, E. (Janssen Pharmaceutica NV) ; Hufkens, V. (Janssen Pharmaceutica NV) ; Jezorwski, J. (Janssen Research & Development) ; Petrovic, R. (Janssen Pharmaceutica NV) ; Brown, K. (Janssen Pharmaceutica NV) ; Van Landuyt, E. (Janssen Pharmaceutica NV) ; Opsomer, M. (Janssen Pharmaceutica NV) ; De Wit, S. (Saint-Pierre University Hospital. Université Libre de Bruxelles) ; Florence, E. (Institute of Tropical Medicine) ; Moutschen, M. (Infectious Diseases department. Liège University Hospital) ; Van Wijngaerden, E. (Department of General Internal Medicine. University Hospitals. KU Leuven - University of Leuven) ; Vandekerckhove, L. (Ghent University and Ghent University Hospital) ; Vandercam, B. (AIDS Reference center. Cliniques Universitaires Saint-Luc) ; Brunetta, J. (Maple Leaf Medical Clinic) ; Conway, B. (Vancouver Infectious Diseases Center) ; Klein, M. (Division of Infectious Diseases. Faculty of Medicine. McGill University Health Centre) ; Murphy, D. (Institut national de santé publique du Québec) ; Rachlis, A. (Sunnybrook Health Sciences Centre) ; Shafran, S. (Department of Medicine. University of Alberta) ; Walmsley, S. (University Health Network) ; Ajana, F. (Infectious Diseases Department. Tourcoing Hospital) ; Cotte, L. (Hospices Civils de Lyon. Hôpital de la Croix-Rousse) ; Girardy, P.M. (University Pierre & Marie Curie) ; Katlama, C. (HIV Clinical Research Unit) ; Molina, J.M. (Department of Infectious Diseases. St-Louis Hospital APHP. University of Paris Diderot) ; Poizot-Martin, I. (Clinical Immuno-Hematology Department. Aix-Marseille University. Sainte-Marguerite University Hospital and Inserm U912) ; Raffi, F. (CHU Hôtel Dieu) ; Rey, D. (Le Trait d'Union. HIV-Infection Care Center. Hôpitaux Universitaires de Strasbourg) ; Reynes, J. (Montpellier University Hospital) ; Teicher, E. (Infectious Diseases Department. APHP. Hôpital Bicêtre) ; Yazdanpanah, Y. ; Gasiorowski, J. (Independent Laboratory for Monitoring Infections among Drug Users at the Department of Infectious Diseases. Liver Disease and Acquired Immune Deficiencies. Wroclaw Medical University) ; Halota, W. (Department of Infectious Diseases and Hepatology. Nicolaus Copernicus University) ; Horban, A. (Medical University of Warsaw. Department for Adult's Infectious Diseases) ; Piekarska, A. (Department of Infectious Diseases and Hepatology. Medical University of Lodz) ; Witor, A. (Regional Hospital. Out-Patient's Clinic for Immune Deficiency) ; Arribas, J.R. (Hospital Universitario La Paz. IdiPAZ) ; Perez-Valero, I. (Department of La Paz Hospital) ; Berenguer, J. (Hospital General Universitario Gregorio Marañón) ; Casado, J. (Department of Infectious Diseases. Ramon y Cajal Hospital) ; Gatell, J.M. (Infectious Diseases Department. HCB) ; Gutiérrez, Félix (Infectious Diseases Unit. Hospital Universitario de Elche) ; Galindo, M.J. (Hospital Clínic Universitari (València)) ; Gutiérrez Macià, Mª Del Mar (Institut d'Investigació Biomèdica Sant Pau) ; Iribarren, J.A. (Hospital Universitario Donostia) ; Knobel, H. (Hospital del Mar (Barcelona, Catalunya)) ; Negredo Puigmal, Eugènia. (Institut Germans Trias i Pujol. Institut de Recerca de la Sida IrsiCaixa) ; Pineda, J.A. (Unit of Infectious Diseases and Microbiology. Hospital Universitario de Valme) ; Podzamczer, D. (Institut d'Investigació Biomèdica de Bellvitge) ; Sogorb, J.P. (HIV Unit. Hospital 12 de Octubre. imas12. UCM) ; Pulido, F. (Hospital General Universitario de Alicante (Alacant, País Valencià)) ; Ricart, C. (Department of Microbiology. School of Medicine. University of Valencia) ; Rivero, A. (Infectious Diseases Unit. Hospital Universitario Reina Sofía. Instituto Maimonides de Investigación Biomedica de Córdoba IMIBIC Cordoba University) ; Santos Gil, I. (Unidad de Enfermedades Infecciosas. Hospital Universitario de la Princesa) ; Blaxhult, A. (Department of Infectious Diseases. Venhälsan. Södersjukhuset) ; Flamholc, L. (Department of Infectious Diseases. Malmö University Hospital) ; Gisslèn, M. (Department of Infectious Diseases. University of Gothenburg) ; Thalme, A. (Department of Infectious Diseases. Karolinska University Hospital) ; Fehr, J. (Division of Infectious Diseases and Hospital Epidemiology. University Hospital Zurich) ; Rauch, A. (Department of Infectious Diseases. Bern University Hospital Inselspital. University of Bern) ; Stoeckle, M. (Division of Infectious Diseases and Hospital Epidemiology. Departments of Medicine and Clinical Research. University Hospital of Basel and University of Basel) ; Clarke, A. (Claude Nicol Centre. Royal Sussex County Hospital. Brighton and Sussex University Hospitals NHS Trust) ; Gazzard, B.G. (St. Stephen's Centre. Department of HIV/Genito-Urinary Medicine. Chelsea and Westminster Hospital) ; Johnson, M.A. (Queen Mary University) ; Orkin, C. (Department of HIV Medicine. Royal Free London NHS Foundation Trust) ; Post, F. (King's College Hospital NHS Foundation Trust) ; Ustianowski, A. (Regional Infectious Diseases Unit. North Manchester General Hospital) ; Waters, L. (University College London Hospital) ; Bailey, J. (Department of Medicine. Johns Hopkins University School of Medicine) ; Benson, P. (Be Well Medical) ; Bhatti, L. (AIDS Healthcare Foundation) ; Brar, I. (Henry Ford Hospital) ; Bredeek, U.F. (Metropolis Medical PC) ; Brinson, C. (Central Texas Clinical Research) ; Crofoot, G. (The Crofoot Research Center) ; Cunningham, D. (Pueblo Family Physicians) ; DeJesus, E. (Pueblo Family Physicians) ; Dietz, C. (Orlando Immunology Center) ; Dretler, R. (HIV Medicine. Kansas City Free Health Clinic) ; Eron, J. (Infectious Disease Specialists of Atlanta) ; Felizarta, F. (Private Practice) ; Fichtenbaum, C. (University of Cincinnati College of Medicine) ; Gallant, J. (Southwest CARE Center) ; Gathe, J. (Therapeutic Concepts) ; Hagins, D. (Georgia Department of Public Health. Chatham Care Center) ; Henn, S. (Whitman-Walker Health) ; Henry, W.K. (Department of Medicine. University of Minnesota Washington University School of Medicine) ; Huhn, G. (Ruth M. Rothstein CORE Center) ; Jain, M. (Department of Internal Medicine. University of Texas Southwestern Medical Center) ; Lucasti, C. (South Jersey Infectious Disease) ; Martorell, C. (Infectious Disease and The Research Institute) ; McDonald, C. (Tarrant County Infectious Disease Associates) ; Mills, A. (Southern California Men's Medical Group) ; Morales-Ramirez, J. (Clinical Research Puerto Rico Inc.) ; Mounzer, K. (Philadelphia FIGHT) ; Nahass, R. (ID Care) ; Olivet, H. (Community Research Initiative of New England) ; Osiyemi, O. (Triple O Research Institute PA) ; Prelutsky, D. (Department of Internal Medicine. Washington University School of Medicine) ; Ramgopal, M. (Midway Immunology Center. Fort Pierce) ; Rashbaum, B. (Capital Medical Associates) ; Richmond, G. (Broward General Medical Center) ; Ruane, P. (Ruane Clinical Research Group) ; Scarsella, A. (Pacific Oaks Medical Group) ; Scribner, A. (DCOL Center for Clinical Research) ; Shalit, P. (Peter Shalit MD and Associates) ; Shamblaw, D. (La Playa Medical Group) ; Slim, J. (Department of Infectious Diseases. Seton Hall University) ; Tashima, K. (The Miriam Hospital. Warren Alpert Medical School of Brown University) ; Voskuhl, G. (AIDS Arms. Inc.) ; Ward, D. (Dupont Circle Physicians Group) ; Wilkin, A. (Wake Forest School of Medicine) ; de Vente, J. (Living Hope Foundation) ; Universitat Autònoma de Barcelona
Darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) 800/150/200/10 mg was investigated through 96 weeks in EMERALD (NCT02269917). Virologically-suppressed, HIV-1-positive treatment-experienced adults (previous non-darunavir virologic failure [VF] allowed) were randomized (2:1) to D/C/F/TAF or boosted protease inhibitor (PI) plus emtricitabine/tenofovir-disoproxil-fumarate (F/TDF) over 48 weeks. [...]
2019 - 10.1016/j.antiviral.2019.104543
Antiviral Research, Vol. 170 (october 2019) , p. 104543  
3.
8 p, 218.5 KB Profile of once-daily darunavir/cobicistat fixed-dose combination for the treatment of HIV/AIDS / Navarro, Jordi (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Curran, Adrian (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Universitat Autònoma de Barcelona
Efficacy is the main objective of antiretroviral treatment and adherence is one of the cornerstones to achieve it. For this reason, treatment simplification is of key importance with regard to antiretroviral regimens. [...]
2016 - 10.2147/HIV.S56158
HIV/AIDS (Auckland, N.Z.), Vol. 8 (october 2016) , p. 175-182  

Us interessa rebre alertes sobre nous resultats d'aquesta cerca?
Definiu una alerta personal via correu electrònic o subscribiu-vos al canal RSS.